Fabhalta vs placebo: 49.3% slower eGFR decline and 43% fewer kidney‑failure events in IgA nephropathy — a progression‑slowing therapy, not a cure
Novartis’ Phase III APPLAUSE‑IgAN trial published in the New England Journal of Medicine and presented at the 2026 World Congress…